医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2014年
12期
26-27
,共2页
夏红%易建华%杨丽%褚桂芬
夏紅%易建華%楊麗%褚桂芬
하홍%역건화%양려%저계분
宫颈肿瘤%化疗%细胞凋亡 Bcl-2蛋白%Bax蛋白
宮頸腫瘤%化療%細胞凋亡 Bcl-2蛋白%Bax蛋白
궁경종류%화료%세포조망 Bcl-2단백%Bax단백
cervical carcinoma%chemotherapy%apoptosis%Bcl-2%Bax
目的：探讨Bax、Bcl-2蛋白在局部晚期宫颈癌（LACC）中的表达及其临床意义。方法应用免疫组化检测47例LACC 组织中化疗前Bax、Bcl-2蛋白的表达情况。结果①47例LACC中，NACT有效率为72.3%，CR 为14.9%。②化疗前，Bax及Bcl-2蛋白阳性表达率分别为：55.3%、36.2%。临床有效及无效病例中，B a x阳性表达率分别为64.7%、38.5%，差异有统计学意义（P<0.05）；B c l-2阳性表达率分别为32.4%、46.2%，差异无统计学意义（P>0.05）。③肿瘤低分化患者中B a x阳性表达率明显低于高中分化患者，有淋巴结转移者明显低于无淋巴结转移者（P<0.05）；而在年龄、病灶大小、病理类型、临床分期方面均无明显差异（P>0.05）。Bcl-2表达在各临床病理参数方面均无明显差异（P>0.05）。结论紫杉醇+顺铂静脉化疗对LACC有效，Bax蛋白异常表达与宫颈癌的生物学行为有关，可作为预测和判定NACT疗效的指标。
目的：探討Bax、Bcl-2蛋白在跼部晚期宮頸癌（LACC）中的錶達及其臨床意義。方法應用免疫組化檢測47例LACC 組織中化療前Bax、Bcl-2蛋白的錶達情況。結果①47例LACC中，NACT有效率為72.3%，CR 為14.9%。②化療前，Bax及Bcl-2蛋白暘性錶達率分彆為：55.3%、36.2%。臨床有效及無效病例中，B a x暘性錶達率分彆為64.7%、38.5%，差異有統計學意義（P<0.05）；B c l-2暘性錶達率分彆為32.4%、46.2%，差異無統計學意義（P>0.05）。③腫瘤低分化患者中B a x暘性錶達率明顯低于高中分化患者，有淋巴結轉移者明顯低于無淋巴結轉移者（P<0.05）；而在年齡、病竈大小、病理類型、臨床分期方麵均無明顯差異（P>0.05）。Bcl-2錶達在各臨床病理參數方麵均無明顯差異（P>0.05）。結論紫杉醇+順鉑靜脈化療對LACC有效，Bax蛋白異常錶達與宮頸癌的生物學行為有關，可作為預測和判定NACT療效的指標。
목적：탐토Bax、Bcl-2단백재국부만기궁경암（LACC）중적표체급기림상의의。방법응용면역조화검측47례LACC 조직중화료전Bax、Bcl-2단백적표체정황。결과①47례LACC중，NACT유효솔위72.3%，CR 위14.9%。②화료전，Bax급Bcl-2단백양성표체솔분별위：55.3%、36.2%。림상유효급무효병례중，B a x양성표체솔분별위64.7%、38.5%，차이유통계학의의（P<0.05）；B c l-2양성표체솔분별위32.4%、46.2%，차이무통계학의의（P>0.05）。③종류저분화환자중B a x양성표체솔명현저우고중분화환자，유림파결전이자명현저우무림파결전이자（P<0.05）；이재년령、병조대소、병리류형、림상분기방면균무명현차이（P>0.05）。Bcl-2표체재각림상병리삼수방면균무명현차이（P>0.05）。결론자삼순+순박정맥화료대LACC유효，Bax단백이상표체여궁경암적생물학행위유관，가작위예측화판정NACT료효적지표。
Objective To investigate the expression and clinical significance of Bax and Bcl-2 before neo-adjuvant chemotherapy (NACT) in local y advanced cervical cancer (LACC) . Methods 47 patients with stage ⅠB2-ⅡB of LACC treated with neoadjuvant chemotherapy(NACT) between January 2010 and December 2013 in our hospital were retrospectively analyzed. The expressions of Bax and Bcl-2 were determined by means of immunohistochemistry before NACT. Results: The total effective rate of NACT was 72.3%, including CR 14.9%. The Bax and Bcl-2 expression was 55.3% and 36.2% before NACT. In patients who react and react poorly to NACT, the expression of Bax was 64.7% and 38.5% (p<0.05), the expression of Bcl-2 was 32.4% and 46.2% (p>0.05). The staining intensity for Bax was related to histopathological grade and lymphatic metastasis (p<0.05), but was not related to age, pathological type and clinical stage (P>0.05). The staining intensity for Bcl-2 was not related to the above clinical and pathological factor (P>0.05). Conclusions The NACT of paclitaxel and cisplatin was effective to LACC. The expression of Bax could be related with biological behavior of the tumor and considered as the index to predict efficacy in NACT.
